Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Gender-related differences in systemic sclerosis.

Hughes M, Pauling JD, Armstrong-James L, Denton CP, Galdas P, Flurey C.

Autoimmun Rev. 2020 Feb 13:102494. doi: 10.1016/j.autrev.2020.102494. [Epub ahead of print] Review.

PMID:
32062031
2.

Patient experiences of digital ulcer development and evolution in systemic sclerosis.

Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A.

Rheumatology (Oxford). 2020 Feb 7. pii: keaa037. doi: 10.1093/rheumatology/keaa037. [Epub ahead of print] No abstract available.

PMID:
32031630
3.

A Multi-Centre Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis.

Hughes M, Pauling JD, Jones J, Denton CP, Domsic RT, Frech TM, Herrick AL, Khanna D, Matucci-Cerinic M, McKenzie L, Saketkoo LA, Gooberman-Hill R, Moore A.

Arthritis Care Res (Hoboken). 2019 Dec 16. doi: 10.1002/acr.24127. [Epub ahead of print]

PMID:
31841265
4.

Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA.

Hamann PDH, Pauling JD, McHugh N, Hyrich K, Shaddick G.

Rheumatology (Oxford). 2019 Nov 12. pii: kez518. doi: 10.1093/rheumatology/kez518. [Epub ahead of print]

PMID:
31714580
5.

Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?

Hughes M, Khanna D, Pauling JD.

Rheumatology (Oxford). 2020 Mar 1;59(3):464-466. doi: 10.1093/rheumatology/kez522. No abstract available.

PMID:
31670800
6.

EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases.

Najm A, Nikiphorou E, Kostine M, Richez C, Pauling JD, Finckh A, Ritschl V, Prior Y, Balážová P, Stones S, Szekanecz Z, Iagnocco A, Ramiro S, Sivera F, Dougados M, Carmona L, Burmester G, Wiek D, Gossec L, Berenbaum F.

RMD Open. 2019 Sep 13;5(2):e001014. doi: 10.1136/rmdopen-2019-001014. eCollection 2019.

7.

Raynaud's phenomenon-an update on diagnosis, classification and management.

Pauling JD, Hughes M, Pope JE.

Clin Rheumatol. 2019 Dec;38(12):3317-3330. doi: 10.1007/s10067-019-04745-5. Epub 2019 Aug 16.

PMID:
31420815
8.

Pauling and Frech reply.

Pauling JD, Frech TM.

J Rheumatol. 2019 Nov;46(11):1544-1545. doi: 10.3899/jrheum.190565. Epub 2019 Jul 15. No abstract available.

PMID:
31308205
9.

Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.

Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K; BSRBR-RA Contributors Group .

Rheumatology (Oxford). 2019 Dec 1;58(12):2162-2169. doi: 10.1093/rheumatology/kez188.

10.

An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Baron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, Domsic RT, Ferdowsi N, Foeldvari I, Frech T, Gordon JK, Hudson M, Johnson SR, Khanna D, McMahan Z, Merkel PA, Narain S, Nikpour M, Pauling JD, Ross L, Valenzuela Vergara AM, Vacca A.

J Scleroderma Relat Disord. 2019 Feb;4(1):17-27. doi: 10.1177/2397198318783926. Epub 2018 Jul 18.

11.

Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis.

Pauling JD, Reilly E, Smith T, Frech TM.

J Rheumatol. 2019 Oct;46(10):1326-1334. doi: 10.3899/jrheum.180818. Epub 2019 Mar 1.

PMID:
30824643
12.

Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.

Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, Ingegnoli F, McHugh NJ, Johnson SR, Hudson M, Boin F, Ong VH, Matucci-Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL.

J Scleroderma Relat Disord. 2018 Oct;3(3):249-252. doi: 10.1177/2397198318774307. Epub 2018 May 24.

13.

The efficacy of dietary intervention on gastrointestinal involvement in systemic sclerosis: A systematic literature review.

Smith E, Pauling JD.

Semin Arthritis Rheum. 2019 Aug;49(1):112-118. doi: 10.1016/j.semarthrit.2018.12.001. Epub 2018 Dec 6. Review.

PMID:
30612705
14.

Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis.

Hamann PDH, Shaddick G, Hyrich K, Green A, McHugh N, Pauling JD; BSRBR-RA Contributors Group.

Rheumatology (Oxford). 2019 May 1;58(5):831-835. doi: 10.1093/rheumatology/key374.

15.

Behaviour change interventions for the management of Raynaud's phenomenon: a systematic literature review.

Daniels J, Pauling JD, Eccleston C.

BMJ Open. 2018 Dec 14;8(12):e024528. doi: 10.1136/bmjopen-2018-024528.

16.

Patient organisation-led initiatives can play an important role in raising awareness about Raynaud's phenomenon and encourage earlier healthcare utilisation for high-risk groups.

Hughes M, Baker A, Farrington S, Pauling JD.

Ann Rheum Dis. 2019 Mar;78(3):439-441. doi: 10.1136/annrheumdis-2018-214161. Epub 2018 Oct 11. No abstract available.

PMID:
30309971
17.

Exploring the patient experience of digital ulcers in systemic sclerosis.

Hughes M, Pauling JD.

Semin Arthritis Rheum. 2019 Apr;48(5):888-894. doi: 10.1016/j.semarthrit.2018.08.001. Epub 2018 Aug 11. Review.

PMID:
30205981
18.

Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patient-Reported Assessments of Disease Severity.

Pauling JD, Reilly E, Smith T, Frech TM.

Arthritis Care Res (Hoboken). 2019 Aug;71(8):1119-1126. doi: 10.1002/acr.23729. Epub 2019 Jul 3.

PMID:
30133174
19.

The Role of Vascular Endothelial Growth Factor in Systemic Sclerosis.

Flower VA, Barratt SL, Ward S, Pauling JD.

Curr Rheumatol Rev. 2019;15(2):99-109. doi: 10.2174/1573397114666180809121005. Review.

PMID:
30091416
20.

Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design.

Hughes M, Tracey A, Bhushan M, Chakravarty K, Denton CP, Dubey S, Guiducci S, Muir L, Ong V, Parker L, Pauling JD, Prabu A, Rogers C, Roberts C, Herrick AL.

J Scleroderma Relat Disord. 2018 Jun 1;3(2):170-174. doi: 10.1177/2397198318764796. Epub 2018 Mar 27.

21.

VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease.

Barratt SL, Flower VA, Pauling JD, Millar AB.

Int J Mol Sci. 2018 Apr 24;19(5). pii: E1269. doi: 10.3390/ijms19051269. Review.

22.

The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis.

Pauling JD.

Expert Rev Clin Immunol. 2018 May;14(5):431-442. doi: 10.1080/1744666X.2018.1464390. Epub 2018 Apr 26. Review.

PMID:
29641934
23.

Qualitative Methods to Advance Care, Diagnosis, and Therapy in Rheumatic Diseases.

Saketkoo LA, Pauling JD.

Rheum Dis Clin North Am. 2018 May;44(2):267-284. doi: 10.1016/j.rdc.2018.01.004. Epub 2018 Feb 21. Review.

24.

Does nailfold capillaroscopy help predict future outcomes in systemic sclerosis? A systematic literature review.

Paxton D, Pauling JD.

Semin Arthritis Rheum. 2018 Dec;48(3):482-494. doi: 10.1016/j.semarthrit.2018.02.005. Epub 2018 Feb 14.

PMID:
29602558
25.

The patient experience of Raynaud's phenomenon in systemic sclerosis.

Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D.

Rheumatology (Oxford). 2019 Jan 1;58(1):18-26. doi: 10.1093/rheumatology/key026. Review.

26.

Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al.

Pauling JD, Saketkoo LA, Domsic RT.

Arthritis Rheumatol. 2018 Jun;70(6):973-974. doi: 10.1002/art.40481. Epub 2018 Apr 29. No abstract available.

27.

Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.

Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1373-1384. doi: 10.1002/acr.23475. Epub 2018 Aug 16.

28.

A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.

Wilkinson JD, Leggett SA, Marjanovic EJ, Moore TL, Allen J, Anderson ME, Britton J, Buch MH, Del Galdo F, Denton CP, Dinsdale G, Griffiths B, Hall F, Howell K, MacDonald A, McHugh NJ, Manning JB, Pauling JD, Roberts C, Shipley JA, Herrick AL, Murray AK.

Arthritis Rheumatol. 2018 Jun;70(6):903-911. doi: 10.1002/art.40457. Epub 2018 Apr 23.

29.

Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis.

Pauling JD, Salazar G, Lu H, Betteridge ZE, Assassi S, Mayes MD, McHugh NJ.

Rheumatology (Oxford). 2018 Apr 1;57(4):712-717. doi: 10.1093/rheumatology/kex458.

PMID:
29294089
30.

Vasodilation is not the only approach to the management of cutaneous ulceration in systemic sclerosis.

Pauling JD.

Rheumatology (Oxford). 2017 Sep 1;56(9):1559. doi: 10.1093/rheumatology/kex175. No abstract available.

PMID:
28859324
31.

Behaviour change interventions for the management of Raynaud's phenomenon: a systematic review protocol.

Daniels J, Pauling JD, Eccelston C.

BMJ Open. 2017 Aug 4;7(8):e017039. doi: 10.1136/bmjopen-2017-017039.

32.

Patient participation in patient-reported outcome instrument development in systemic sclerosis.

Pauling JD, Frech TM, Domsic RT, Hudson M.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):184-192. Epub 2017 May 2. Review.

33.

Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis.

Bissell LA, Anderson M, Burgess M, Chakravarty K, Coghlan G, Dumitru RB, Graham L, Ong V, Pauling JD, Plein S, Schlosshan D, Woolfson P, Buch MH.

Rheumatology (Oxford). 2017 Jun 1;56(6):912-921. doi: 10.1093/rheumatology/kew488.

34.

Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease.

McCarthy EM, Moreno-Martinez D, Wilkinson FL, McHugh NJ, Bruce IN, Pauling JD, Alexander MY, Parker B.

BBA Clin. 2016 Nov 10;7:16-22. doi: 10.1016/j.bbacli.2016.11.003. eCollection 2017 Jun.

35.

Could nailfold videocapillaroscopy usher in a new era of preventative disease-modifying therapeutic intervention in systemic sclerosis?

Pauling JD.

Rheumatology (Oxford). 2017 Jul 1;56(7):1053-1055. doi: 10.1093/rheumatology/kew461. No abstract available.

PMID:
28039415
36.

Orofacial manifestations of systemic sclerosis.

Veale BJ, Jablonski RY, Frech TM, Pauling JD.

Br Dent J. 2016 Sep 23;221(6):305-10. doi: 10.1038/sj.bdj.2016.678.

PMID:
27659631
37.

Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor.

Hamann P, Holland R, Hyrich K, Pauling JD, Shaddick G, Nightingale A, McHugh N.

Arthritis Care Res (Hoboken). 2017 Jun;69(6):783-793. doi: 10.1002/acr.23016. Epub 2017 May 8. Review.

38.

Symptoms of Raynaud's phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology.

Scolnik M, Vasta B, Hart DJ, Shipley JA, McHugh NJ, Pauling JD.

Rheumatol Int. 2016 Oct;36(10):1371-7. doi: 10.1007/s00296-016-3483-6. Epub 2016 May 2.

39.

Sublingual Abnormalities in Systemic Sclerosis.

Frech TM, Pauling JD, Murtaugh MA, Kendall K, Domsic RT.

J Clin Rheumatol. 2016 Jan;22(1):19-21. doi: 10.1097/RHU.0000000000000339.

40.

Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary.

Pauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ.

J Rheumatol. 2015 Jul;42(7):1163-8. doi: 10.3899/jrheum.141437. Epub 2015 Jun 1.

PMID:
26034146
41.

Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease.

Gunn J, Pauling JD, McHugh NJ.

Clin Rheumatol. 2014 Jun;33(6):869-71. doi: 10.1007/s10067-014-2616-0. Epub 2014 Apr 22.

PMID:
24752346
42.

Abnormal cardiac enzymes in systemic sclerosis: a report of four patients and review of the literature.

Vasta B, Flower V, Bucciarelli-Ducci C, Brown S, Korendowych E, McHugh NJ, Pauling JD.

Clin Rheumatol. 2014 Mar;33(3):435-8. doi: 10.1007/s10067-013-2405-1. Epub 2013 Oct 3. Review.

PMID:
24091585
43.

The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis.

Pauling JD, O'Donnell VB, Mchugh NJ.

Platelets. 2013;24(7):503-15. doi: 10.3109/09537104.2012.719090. Epub 2012 Sep 11. Review.

PMID:
22966961
44.

Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis.

Pauling JD, Shipley JA, Harris ND, McHugh NJ.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S103-15. Epub 2012 May 30. Review.

PMID:
22691218
45.

Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice?

Pauling JD, McHugh NJ.

Clin Rheumatol. 2012 Feb;31(2):357-61. doi: 10.1007/s10067-011-1844-9. Epub 2011 Sep 13.

PMID:
21912881
46.

Comparison of infrared thermography and laser speckle contrast imaging for the dynamic assessment of digital microvascular function.

Pauling JD, Shipley JA, Raper S, Watson ML, Ward SG, Harris ND, McHugh NJ.

Microvasc Res. 2012 Mar;83(2):162-7. doi: 10.1016/j.mvr.2011.06.012. Epub 2011 Jul 1.

PMID:
21763703
47.

Influence of the cold challenge on the discriminatory capacity of the digital distal-dorsal difference in the thermographic assessment of Raynaud's phenomenon.

Pauling JD, Flower V, Shipley JA, Harris ND, McHugh NJ.

Microvasc Res. 2011 Nov;82(3):364-8. doi: 10.1016/j.mvr.2011.03.007. Epub 2011 Mar 21.

PMID:
21420982
48.

Raynaud's phenomenon and macrocytic anaemia.

Flower V, Pauling JD, Shipley JA, McHugh NJ.

BMJ. 2010 Dec 8;341:c6011. doi: 10.1136/bmj.c6011. No abstract available.

PMID:
21147732
49.

Vacuum-assisted closure therapy: a novel treatment for wound healing in systemic sclerosis.

Pauling JD, Brown SJ, James J, Shipley JA, Korendowych E, McHugh NJ.

Rheumatology (Oxford). 2011 Feb;50(2):420-2. doi: 10.1093/rheumatology/keq319. Epub 2010 Oct 19. No abstract available.

PMID:
20959357
50.

Impaired digital vascular function mimicking Raynaud's phenomenon as a complication of argon laser therapy in tuberous sclerosis.

Pauling JD, Shipley JA, McHugh NJ.

Microvasc Res. 2010 Jul;80(1):2. doi: 10.1016/j.mvr.2010.03.006. Epub 2010 Mar 18. No abstract available.

PMID:
20303994

Supplemental Content

Loading ...
Support Center